The Tumor Necrosis Factor Receptor Superfamily Member 4 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Receptor Superfamily Member 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Dermatology, Immunology, and Gastrointestinal which include the indications Solid Tumor, Unspecified Cancer, Atopic Dermatitis (Atopic Eczema), Prurigo, Inflammation, Unspecified Immunological Disorders, Ulcerative Colitis, and Inflammatory Bowel Disease. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Receptor Superfamily Member 4 pipeline targets constitutes close to 42 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 3, 11, 3, 14, and 6 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Tumor Necrosis Factor Receptor Superfamily Member 4 overview
Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.
For a complete picture of Tumor Necrosis Factor Receptor Superfamily Member 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
